Florida Cancer Specialists will pay $100 million as a criminal penalty for antitrust violations; CMS will exclude spending associated with the coronavirus disease 2019 pandemic from accountable care organization (ACO) performance calculations; the Department of Veterans Affairs orders $300,000 worth of body bags.
Florida Cancer Specialists & Research Institute LLC (FCS) has admitted to antitrust violations and agreed to pay a $100 million criminal penalty, according to the United States Department of Justice. The oncology group based out of Fort Meyers, Florida, was charged with conspiring to allocate medical and radiation oncology treatments for patients with cancer in Southwest Florida. The criminal antitrust conspiracy involved a competing oncology group located in Collier, Lee, and Charlotte counties. The conspiracy began as early as 1999 and continued until at least 2016, limiting valuable care choices for patients with cancer in Florida for nearly 2 decades.
In an interim final ruling, CMS agreed to remove spending associated with coronavirus disease 2019 (COVID-19) care from performance calculations for accountable care organizations (ACOs) in the Medicare Shared Savings Program (MSSP). CMS will also extend its mitigation of shared losses back to January 2020, ultimately providing flexibility for ACOs to stay in their same risk track next year, according to a press release from the National Association of ACOs (NAACOS). The Association hopes this will help sustain participation in the MSSP for 2020. However, NAACOS expressed disappointment that the ruling did not include an application period in 2021 for new ACOs.
The Department of Veterans Affairs (VA) ordered nearly $300,000 worth of body bags in response to the rising numbers of COVID-19 cases plaguing its healthcare facilities, according to Politico. Currently more than 8500 VA patients have been diagnosed with the disease and nearly 500 have died. It is unclear whether the VA made the purchase in anticipation of a spike in deaths or to redistribute them to other organizations. The purchase comes after a report that nearly 2000 VA health workers have fallen ill with COVID-19, posing a challenge to delivering optimal care for patients.
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Complete Responses Seen With Emerging Therapies for Chronic Spontaneous Urticaria
April 16th 2025There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More